Login to Your Account

FDA Rejects Arpida's Iclaprim as Company Seeks a Partner

By Cormac Sheridan

Wednesday, January 21, 2009
Although the news was hardly a surprise, shares in Arpida AG still dropped by more than 4 percent Tuesday, following confirmation from the FDA that it would require additional clinical data to approve the Swiss firm's antibiotic iclaprim. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription